Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL72939 | 1.00 | CA4 (0.46) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL153476 | 1.00 | CA4 (0.46) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL150638 | 1.00 | CA4 (0.46) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL28576576 | 1.00 | CA4 (0.46) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL1401747 | 1.00 | CA4 (0.46) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL22476039 | 1.00 | CA4 (0.46) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL3237788 | 0.94 | — | — | |
| Bicarbonate SCHEMBL14563499 | 0.94 | CA4 (0.42) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL40504 | 0.94 | CA4 (0.50) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL14563712 | 0.89 | CA4 (0.39) | CA4CA1FAHD1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115849429-B | Preparation method of small-particle-size lanthanum carbonate tetrahydrate | 湖南明瑞制药股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-114477265-B | Preparation method of lanthanum carbonate tetrahydrate | 南京正济医药研究有限公司 | 2023-11-03 | — | — | CN | claimed |
| US-20230227322-A1 | METHOD FOR PREPARING LANTHANUM CARBONATE TETRAHYDRATE AND PRODUCT THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2023-07-20 | — | — | US | claimed |
| EP-4166503-A1 | METHOD FOR PREPARING LANTHANUM CARBONATE TETRAHYDRATE AND PRODUCT THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2023-04-19 | — | — | EP | claimed |
| CN-115849429-A | Preparation method of small-particle-size lanthanum carbonate tetrahydrate | 湖南明瑞制药股份有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-113244179-B | Lanthanum carbonate tablet with good stability, preparation method and application thereof | 浙江仟源海力生制药有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-114477265-A | Preparation method of lanthanum carbonate tetrahydrate | 南京正济医药研究有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-114486963-A | XRD detection method for impurities in lanthanum hydroxycarbonate | 珠海润都制药股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-113244179-A | Lanthanum carbonate tablet with good stability, preparation method and application thereof | 浙江仟源海力生制药有限公司 | 2021-08-13 | — | — | CN | claimed |
| CN-111620363-A | Preparation method of lanthanum carbonate tetrahydrate and product thereof | 南京卡文迪许生物工程技术有限公司 | 2020-09-04 | — | — | CN | claimed |
| US-20140178467-A1 | CAPSULE AND POWDER FORMULATIONS CONTAINING LANTHANUM COMPOUNDS | SHIRE LLC (US) | 2014-06-26 | — | — | US | claimed |
| CN-101590076-B | Application of pharmacologically-acceptable metal lanthanum salt or lanthanum oxide | SHENGYANG PHARMTECH PHARMACEUTICAL R & D LTD | 2013-04-10 | — | — | CN | claimed |
| US-20100092576-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING LANTHANUM HYDROXYCARBONATE | SHIRE INTERNATIONAL LICENSING B.V. (NL) | 2010-04-15 | — | — | US | claimed |
| US-20100015246-A1 | COMBINATION OF A LANTHANUM COMPOUND AND BONE ENHANCING AGENT FOR THE TREATMENT OF BONE DISEASES | SHIRE INTERNATIONAL LICENSING B.V. (NL) | 2010-01-21 | — | — | US | claimed |
| CN-101590076-A | The purposes of lanthanoid metal pharmaceutically acceptable salt or its oxide | SHENGYANG PHARMTECH PHARMACEUT (CN) | 2009-12-02 | — | — | CN | claimed |
| EP-1294384-B1 | USE OF LANTHANUM COMPOUNDS FOR THE TREATMENT OF BONE DISEASES | SHIRE HOLDINGS AG (CH) | 2009-03-11 | — | — | EP | claimed |
| US-20070048390-A1 | Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases | SHIRE INTERNATIONAL LICENSING B.V. (NL) | 2007-03-01 | — | — | US | claimed |
| US-7078059-B2 | Treatment of bone diseases | SHIRE HOLDINGS AG (CH) | 2006-07-18 | — | — | US | claimed |
| CN-121446513-B | High-stability high-activity methanation catalyst for synthesis gas and preparation method thereof | 湖北荟煌科技股份有限公司 | 2026-03-17 | — | — | CN | disclosed |
| WO-2002000227-A2 | USE OF LANTHANUM COMPOUNDS FOR THE TREATMENT OF BONE DISEASES | SHIRE HOLDINGS AG (CH) | 2002-01-03 | — | — | WO | disclosed |